More crossovers join Cedilla’s series B, bringing total to $82.6M

A year after Third Rock-backed Cedilla revealed the first close of its series B round, the biotech has added more crossover investors to cap the round at $82.6 million, preparing it for IND-enabling studies of its two lead programs.

Launched in 2018 and backed initially by Third Rock Ventures, the sole investor in its series A round, Cedilla Therapeutics Inc. is seeking to reach historically undruggable oncogenic targets by modulating them in specific functional states...